Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

Eitemau Tebyg

• 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
  gan: Kuroki, Hiroo, et al.
  Cyhoeddwyd: (2019)
• Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
  gan: Kuroki, Hiroo, et al.
  Cyhoeddwyd: (2021)
• GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
  gan: Karmali, Reem, et al.
  Cyhoeddwyd: (2017)
• ATPS-91 GSK-3 INHIBITOR 9-ING-41 ENHANCES GENOTOXIC THERAPY OF GBM LEADING TO CURE FROM INTRACRANIAL BRAIN TUMOR
  gan: Ugolkov, Andrey, et al.
  Cyhoeddwyd: (2015)
• Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()
  gan: Ugolkov, Andrey, et al.
  Cyhoeddwyd: (2017)